Citadel Advisors’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Citadel Advisors’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,204,252	Closed	-$42.1M	–	15898
2024 Q1	$42.1M	Buy	1,204,252 +949,414	+373%	+$34.6M	0.01%	1366
2023 Q4	$9.68M	Buy	254,838 +12,028	+5%	+$258K	﹤0.01%	2888
2023 Q3	$4.46M	Buy	242,810 +175,999	+263%	+$3.68M	﹤0.01%	3848
2023 Q2	$1.73M	Buy	66,811 +47,232	+241%	+$1.1M	﹤0.01%	5410
2023 Q1	$369K	Sell	19,579 -39,328	-67%	-$915K	﹤0.01%	8948
2022 Q4	$1.45M	Buy	58,907 +4,893	+9%	+$144K	﹤0.01%	6096
2022 Q3	$969K	Buy	54,014 +9,482	+21%	+$171K	﹤0.01%	7061
2022 Q2	$506K	Sell	44,532 -96,933	-69%	-$1.43M	﹤0.01%	8627
2022 Q1	$3.15M	Buy	141,465 +131,778	+1,360%	+$3.36M	﹤0.01%	5065
2021 Q4	$423K	Buy	+9,687	New	+$387K	﹤0.01%	10079

Other funds holding INBX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Citadel Advisors's INBX Position: Q2 2024 in Review

Citadel Advisors sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 1,204,252 shares — an estimated $42.1M sold.

Citadel Advisors first reported a position in INBX in Q4 2021 and held it in 10 quarters. The position peaked at $42.1M in Q1 2024. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.

Citadel Advisors reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Citadel Advisors sold 1,204,252 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $42.1M.
Citadel Advisors first reported a position in Inhibrx, Inc. Common Stock in Q4 2021 and held it in 10 quarters.
Citadel Advisors's Inhibrx, Inc. Common Stock position peaked at $42.1M in Q1 2024.
2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.

Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.